{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-006806","form_type":"8-K","ticker":null,"cik":"0001792581","company_name":"Kiromic Biopharma, Inc.","filed_at":"2024-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.137735+00:00","generated_at":"2026-06-02T22:17:50.210018+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Kiromic BioPharma issues $2M 25% senior secured convertible note due May 2025","bullets":["Principal $2,000,000, 25% annual interest (27% on default), matures May 1, 2025.","Convertible into common stock at $2.50/share, subject to 19.99% beneficial ownership limitation.","Note is senior secured by all company fixtures, equipment, and intellectual property.","Issued to an accredited investor in reliance on Section 4(a)(2) exemption.","Company may prepay without penalty on 10 days' notice; Holder may convert until prepaid."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-006806","json":"https://secwatch.observer/filing/0001558370-24-006806.json","markdown":"https://secwatch.observer/filing/0001558370-24-006806.md","text":"https://secwatch.observer/filing/0001558370-24-006806.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1792581/000155837024006806/0001558370-24-006806-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1792581/000155837024006806/krbp-20240501x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T22:17:50.210018+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6cd99f4ebe031157bca1520d94446102c5f3793a","claim":"Kiromic Biopharma, Inc. incurred convertible notes of principal amount of $2,000,000 with an accredited investor at interest at a rate of 25% per annum (the “Stated Rate”) maturing matures on May 1, 2025.","evidence_excerpt":"On May 1, 2024, Kiromic BioPharma, Inc. (the “Company”) issued a 25% Senior Secured Convertible Promissory Note (the “Note”) to an accredited investor. The Note has a principal amount of $2,000,000, bears interest at a rate of 25% per annum (the “Stated Rate”) and matures on May 1, 2025 (the “Maturity Date”), on which the principal balance and accrued but unpaid interest under the Note shall be due and payable.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1792581/000155837024006806/0001558370-24-006806-index.htm","confidence":0.95,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"principal amount of $2,000,000"},{"label":"Counterparty","value":"an accredited investor"},{"label":"Rate","value":"interest at a rate of 25% per annum (the “Stated Rate”)"},{"label":"Maturity","value":"matures on May 1, 2025"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"2273a3df22e7a698f56ff23e8526e00fdc41ce88","claim":"Kiromic Biopharma, Inc. entered into 25% Senior Secured Convertible Promissory Note with an accredited investor valued at $2,000,000 (effective 2024-05-01).","evidence_excerpt":"On May 1, 2024, Kiromic BioPharma, Inc. (the “Company”) issued a 25% Senior Secured Convertible Promissory Note (the “Note”) to an accredited investor.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1792581/000155837024006806/0001558370-24-006806-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"an accredited investor"},{"label":"Value","value":"$2,000,000"},{"label":"Effective","value":"2024-05-01"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}